Literature DB >> 6753555

Immune reactions in tuberculous and chronic constrictive pericarditis. Clinical data and diagnostic significance of antimyocardial antibodies.

B Maisch, S Maisch, K Kochsiek.   

Abstract

Humoral immune reactions were analyzed in 12 patients with exudative tuberculous pericarditis, 10 patients with constrictive pericarditis due to former tuberculosis, 10 patients with viral pericarditis, 20 patients with pulmonary tuberculosis, and 98 healthy donors. Pericarditis occurred in 12.5% of the patients with tuberculosis, whereas the incidence of tuberculosis in the 149 patients with pericarditis was 8%. Repeated pericardial puncture and pericardial effusions of greater than 500 ml with impending cardiac tamponade had to be performed in 4 patients. Clinical data indicated probable myocardial involvement in 4 of 12 patients. Antimyolemmal antibodies, which are a muscle-specific subtype of antisarcolemmal antibodies, were found in all patients with exudative tuberculous pericarditis and viral perimyocarditis, in only 1 of 12 patients with constrictive pericarditis, and in no patients with pulmonary tuberculosis. Antifibrillary antibodies--primarily of the antimyosin type--were missed in patients with viral heart disease but were demonstrated in 75% of patients with tuberculous pericarditis. Only sera with complement-fixing antimyolemmal antibodies of the IgG type in titers greater than 1:40 induced cytolysis of vital adult heterologous cardiocytes isolated and enriched by silica sol gradient centrifugation. These findings suggest not only that antimyolemmal antibodies are diagnostic indicators of perimyocardial involvement in tuberculous pericarditis, but also that they may play a significant role in its pathogenesis.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6753555     DOI: 10.1016/0002-9149(82)90409-x

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  10 in total

Review 1.  Tuberculous pericarditis with and without HIV.

Authors:  Mpiko Ntsekhe; Bongani M Mayosi
Journal:  Heart Fail Rev       Date:  2013-05       Impact factor: 4.214

Review 2.  Humoral immune response to cardiac conducting tissue.

Authors:  U Lotze; B Maisch
Journal:  Springer Semin Immunopathol       Date:  1989

Review 3.  Autoreactivity to the cardiac myocyte, connective tissue and the extracellular matrix in heart disease and postcardiac injury.

Authors:  B Maisch
Journal:  Springer Semin Immunopathol       Date:  1989

Review 4.  The classification of pericardial disease in the age of modern medicine.

Authors:  Bernhard Maisch; Arsen D Ristić
Journal:  Curr Cardiol Rep       Date:  2002-01       Impact factor: 2.931

5.  Detection of anti-contractile antibodies after cardiac surgery using ELISA assay.

Authors:  I De Scheerder; J Vandekerckhove; G De Schrijver; M Hoste; D Clement; R Wieme; R Pannier
Journal:  Clin Exp Immunol       Date:  1985-05       Impact factor: 4.330

6.  Rickettsial perimyocarditis--a follow-up study.

Authors:  B Maisch
Journal:  Heart Vessels       Date:  1986       Impact factor: 2.037

7.  Recombinant cardiac myosin fragment induces experimental autoimmune myocarditis via activation of Th1 and Th17 immunity.

Authors:  Melvin D Daniels; Kenneth V Hyland; Kegiang Wang; David M Engman
Journal:  Autoimmunity       Date:  2008-09       Impact factor: 2.815

8.  Immunologic regulator and effector mechanisms in myocarditis and perimyocarditis.

Authors:  B Maisch
Journal:  Heart Vessels Suppl       Date:  1985

Review 9.  Established and novel pathophysiological mechanisms of pericardial injury and constrictive pericarditis.

Authors:  Vinasha Ramasamy; Bongani M Mayosi; Edward D Sturrock; Mpiko Ntsekhe
Journal:  World J Cardiol       Date:  2018-09-26

10.  Anticardiac Antibodies in Patients with Chronic Pericardial Effusion.

Authors:  Konstantinos Karatolios; Sabine Pankuweit; Anette Richter; Volker Ruppert; Bernhard Maisch
Journal:  Dis Markers       Date:  2016-01-28       Impact factor: 3.434

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.